Close
Smartlab Europe
Inizio Ignite

News

A New Senate & its implications on The Pharmaceutical Sector?

The US elections make big news whenever they occur. The fact that who comes to power has a phenomenal effect on all industries, big or small. One such industry that is bracing for the impact is the Pharmaceutical Sector....

AstraZeneca Says Calquence Approved In The EU For CLL

AstraZeneca’s Calquence (acalabrutinib), a next-generation selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults. The approval...

Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA

Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced that the U.S. FDA has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate. Currently in late-phase clinical development, NVXCoV2373 is a stable,...

Llama nanobodies could be a powerful weapon against COVID-19

The researchers at the University of Pittsburgh School of Medicine describe a new method to extract tiny but extremely powerful SARS-CoV-2 antibody fragments from llamas, which could be fashioned into inhalable therapeutics with the potential to prevent and treat...

Oxford Biomedica and PhoreMost enter gene therapy discovery collaboration

Oxford Biomedica plc , a leading gene and cell therapy group and PhoreMost Limited, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, announced that they have entered into a discovery collaboration to develop next-generation CAR-T...

CDMOs benefit from COVID-19 impacts but mega-cap pharma innovation slowing outsourcing according to CPhI Annual Report

The global contact services sector is benefiting from a switch towards COVID-19 manufacturing (vaccine and therapy) and clinical stage contracts, but mega-cap innovator drug approvals are reducing commercial demand according to the CPhI Annual Report contract services findings. Adam Bradbury,...

Pfizer Announces Positive Phase 3 Study Results for XELJANZ in Ankylosing Spondylitis

Pfizer Inc. announced positive results from a Phase 3 investigational study evaluating the safety and efficacy of tofacitinib in adults with active ankylosing spondylitis (AS). Tofacitinib is not currently approved by the U.S. Food and Drug Administration (FDA) for...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »